Inotiv Announces Preliminary Expected Q4 Revenue Of $137.5M - $138.5M And Preliminary Expected FY25 Revenue Of $512.5M - $513.5M

Author: Benzinga Newsdesk | November 17, 2025 04:09pm

Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million

Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million

Updated Time of Company Presentation at Jefferies Global Healthcare Conference  

WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced select preliminary financial results for the fourth quarter ("Q4 FY 2025") and full year ("FY 2025") ended September 30, 2025.

Preliminary Fourth Quarter 2025 Highlights

• Anticipate revenue between $137.5 million and $138.5 million for Q4 FY 2025
• Book-to-bill ratio for Q4 FY 2025 is anticipated to be approximately 1.08x for the DSA services business
• Anticipated DSA backlog of approximately $138.0 million at September 30, 2025, compared to $129.9 million at September 30, 2024, and $134.3 million at June 30, 2025
   

Preliminary FY 2025 Highlights

• Anticipate revenue between $512.5 million and $513.5 million for FY 2025
• Book-to-bill ratio for FY 2025 is anticipated to be approximately 1.05x for the DSA services business

Posted In: NOTV